Sex steroids have been widely described in the scientific literature to be associated with a number of human diseases, including cancers. The most known tumors related to sex steroid hormones are hormone-dependent cancers such as prostate, ovarian, breast and endometrial cancers. To date, the classical therapy consists of hormone-deprivation but, in most cases, though the steroid receptors are yet expressed, the cancers develop resistance and become pharmacologically uncontrolled.
Apart from the classical hormone-dependent cancers, several studies shown that other tumors such as pancreatic and colorectal cancer, melanoma and different kinds of sarcoma could be controlled by sex steroid hormones and receptors and, sometimes, their incidence is influenced by circulating hormone levels in humans. Studies about the role of sex steroid hormones and their receptors in all type of cancers could be useful to develop new effective and specific therapies for different kinds of cancers.
This Research Topic invites contributions (clinical, molecular, translational data) which explore the role of sex steroid hormones and the receptors by which they act (their specific receptors but also glucocorticoid receptors, GPR30, AR and ER alpha isoforms and so on) in different kind of cancers. Original Research, Review, and Clinical Trial articles on these topics are all welcomed.
This Research topic aims to produce a comprehensive collection of broad knowledge in this field, ranging from biomolecular processes to effective therapies for treating cancers targeting sex steroid receptors, from basic research to clinical practice.
Potential topics include but are not limited to the following:
• Role of sex steroid hormones and receptors in cancer progression.
• Role of sex steroid hormones and their receptors on tumor microenvironment.
• Novel therapies targeting sex steroid receptors in cancers.
• Aberrations of signaling pathways by sex steroid hormones and receptors in cancers.
• Recent translational advances and clinical outcomes in cancers.
• Tailored immunotherapy by regulating genomic and proteomic expressions.
Sex steroids have been widely described in the scientific literature to be associated with a number of human diseases, including cancers. The most known tumors related to sex steroid hormones are hormone-dependent cancers such as prostate, ovarian, breast and endometrial cancers. To date, the classical therapy consists of hormone-deprivation but, in most cases, though the steroid receptors are yet expressed, the cancers develop resistance and become pharmacologically uncontrolled.
Apart from the classical hormone-dependent cancers, several studies shown that other tumors such as pancreatic and colorectal cancer, melanoma and different kinds of sarcoma could be controlled by sex steroid hormones and receptors and, sometimes, their incidence is influenced by circulating hormone levels in humans. Studies about the role of sex steroid hormones and their receptors in all type of cancers could be useful to develop new effective and specific therapies for different kinds of cancers.
This Research Topic invites contributions (clinical, molecular, translational data) which explore the role of sex steroid hormones and the receptors by which they act (their specific receptors but also glucocorticoid receptors, GPR30, AR and ER alpha isoforms and so on) in different kind of cancers. Original Research, Review, and Clinical Trial articles on these topics are all welcomed.
This Research topic aims to produce a comprehensive collection of broad knowledge in this field, ranging from biomolecular processes to effective therapies for treating cancers targeting sex steroid receptors, from basic research to clinical practice.
Potential topics include but are not limited to the following:
• Role of sex steroid hormones and receptors in cancer progression.
• Role of sex steroid hormones and their receptors on tumor microenvironment.
• Novel therapies targeting sex steroid receptors in cancers.
• Aberrations of signaling pathways by sex steroid hormones and receptors in cancers.
• Recent translational advances and clinical outcomes in cancers.
• Tailored immunotherapy by regulating genomic and proteomic expressions.
